GlassScriptPhysician profile
Sandra Y Cho
NPI 1023056306
$1,931.77
in general payments reported to CMS, 2019-2025
21 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $86.69 · 2021: $165 · 2022: $191 · 2023: $431 · 2024: $407 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $238.30 | 2019-2025 | Cequa |
| Alcon Vision LLC | $230.29 | 2022-2025 | Rocklatan, Clareon, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $217.42 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $176.90 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $164.34 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Glaukos Corporation | $159.40 | 2020-2025 | Idosetr |
| Abbvie INC. | $139.13 | 2022-2024 | Lumigan, Vuity, Alphagan P |
| Ocular Therapeutix, INC. | $111.22 | 2023-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.26 | 2019-2021 | |
| Allergan, INC. | $93.32 | 2019-2021 | |
| Dompe US, INC. | $49.96 | 2021-2024 | Oxervate |
| Thea Pharma INC. | $40.35 | 2023 | Iyuzeh |
| Horizon Therapeutics Plc | $37.23 | 2021-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $32.11 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $22.29 | 2025 | Catalys System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.95 | 2023 | |
| Kala Pharmaceuticals, INC. | $20.18 | 2021 | |
| Omeros Corporation | $19.07 | 2019 | |
| Alcon Research LLC | $17.25 | 2019 | |
| Eyevance Pharmaceuticals LLC | $15.92 | 2021 | |
| Shire North American Group INC | $15.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.